- Ticagrelor - brief drug profile2015 | First Faculty of Medicine
- PEGASUS-TIMI 54: Long-term use of ticagrelor in patients with prior myocardial infarction2015 | First Faculty of Medicine
- The EUCLID Study (Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease)2018 | First Faculty of Medicine
- Ticagrelor - first reversible inhibitor of ADP receptor P2Y122011 | Third Faculty of Medicine
- Ticagrelor v léčbě akutního koronárního syndromu2013 | Third Faculty of Medicine
- News in secondary prevention of atherothrombotic events - focus on ticagrelor2016 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. D5135C00001 +1Publication without faculty affiliation
- Ticagrelor2011 | Third Faculty of Medicine
- In what extent we reached the standards of antiplatelet therapy in secondary prevention of myocardial infarction2019 | Faculty of Medicine in Pilsen
- Refuting the Ticagrelor-Aspirin Black Box Warning: And Proposing a Ticagrelor Early-PCI Black Box Warning2013 | Second Faculty of Medicine
- Report of University Hospital Hradec Králové to the clinical trial protocol No: D5134C0001Publication without faculty affiliation
- News In contemporary management of acute coronary syndromes2014 | Faculty of Medicine in Pilsen
- Clopidogrel is safer than ticagrelor in regard to bleeds: A closer look at the PLATO trial2013 | Second Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. D5134C00001Publication without faculty affiliation
- What is the optimal strategy of prehospital pretreatment of STEMI patients with P2Y12 inhibitors? Experience from Pilsner region in the years 2013-20142016 | Faculty of Medicine in Pilsen
- Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel2013 | Second Faculty of Medicine
- Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial2013 | Second Faculty of Medicine
- Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?2015 | Second Faculty of Medicine
- Missed bleeding events after ticagrelor in PEGASUS trial: Massive non-compliance, information censoring, or both?2016 | Second Faculty of Medicine
- 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor2018 | Third Faculty of Medicine, First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?2016 | Second Faculty of Medicine
- Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial2020 | Third Faculty of Medicine, Central Library of Charles University
- Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction2016 | Third Faculty of Medicine, Faculty of Mathematics and Physics
- Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction2015 | Second Faculty of Medicine
- Antiplatelet therapy in acute coronary syndromes2010 | Publication without faculty affiliation
- CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants2020 | Third Faculty of Medicine
- Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention Multicenter Randomized PRAGUE-18 Study2016 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Ticagrelor in Patients with Stable Coronary Disease and Diabetes2019 | Third Faculty of Medicine
- The clinical importance of antiplatelet resistance and its potential solution2012 | Faculty of Medicine in Pilsen
